Cargando…

Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis

Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chlo...

Descripción completa

Detalles Bibliográficos
Autores principales: Malhotra, Sakshi, Khare, Anubha, Grover, Kanchan, Singh, Inderbir, Pawar, Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590801/
https://www.ncbi.nlm.nih.gov/pubmed/26556196
http://dx.doi.org/10.1155/2014/490595
_version_ 1782392982505259008
author Malhotra, Sakshi
Khare, Anubha
Grover, Kanchan
Singh, Inderbir
Pawar, Pravin
author_facet Malhotra, Sakshi
Khare, Anubha
Grover, Kanchan
Singh, Inderbir
Pawar, Pravin
author_sort Malhotra, Sakshi
collection PubMed
description Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chloride BAK and EDTA with or without viscosity modifiers and study its permeation characteristics through freshly excised goat cornea. The results were observed that viscosity and force of bioadhesion of the voriconazole HP-β-CD solutions containing xanthan gum (XG) are more as compared to polyvinyl alcohol. The results revealed that voriconazole drop containing PVA provided least viscosity and higher corneal permeation of drug, while drop formulated with XG had maximum viscosity and least permeation. The HP-β-CD based voriconazole (1.5%) ophthalmic formulation containing xanthan gum (1.5), preserved with BAK and EDTA, could provide shelf life of 2 years. The microbiological studies showed that voriconazole ophthalmic solution containing xanthan gum shows better antifungal activity as compared to voriconazole and xanthan gum alone. Thus, it can be concluded that HP-β-CD based voriconazole (1.5%, pH 7.0) ophthalmic solution containing BAK and EDTA with viscosity modifier XG provided maximum precorneal residence time as compared to other viscosity modifiers and polyvinyl alcohol provided less precorneal residence time than other viscosity modifiers.
format Online
Article
Text
id pubmed-4590801
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-45908012015-10-13 Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis Malhotra, Sakshi Khare, Anubha Grover, Kanchan Singh, Inderbir Pawar, Pravin J Pharm (Cairo) Research Article Voriconazole is a novel antifungal agent with excellent broad spectrum activity commercially available for oral and intravenous administration. The purpose of this study was to prepare ophthalmic formulation of hydroxypropyl beta cyclodextrin (HP-β-CD) based voriconazole containing benzalkonium chloride BAK and EDTA with or without viscosity modifiers and study its permeation characteristics through freshly excised goat cornea. The results were observed that viscosity and force of bioadhesion of the voriconazole HP-β-CD solutions containing xanthan gum (XG) are more as compared to polyvinyl alcohol. The results revealed that voriconazole drop containing PVA provided least viscosity and higher corneal permeation of drug, while drop formulated with XG had maximum viscosity and least permeation. The HP-β-CD based voriconazole (1.5%) ophthalmic formulation containing xanthan gum (1.5), preserved with BAK and EDTA, could provide shelf life of 2 years. The microbiological studies showed that voriconazole ophthalmic solution containing xanthan gum shows better antifungal activity as compared to voriconazole and xanthan gum alone. Thus, it can be concluded that HP-β-CD based voriconazole (1.5%, pH 7.0) ophthalmic solution containing BAK and EDTA with viscosity modifier XG provided maximum precorneal residence time as compared to other viscosity modifiers and polyvinyl alcohol provided less precorneal residence time than other viscosity modifiers. Hindawi Publishing Corporation 2014 2014-04-29 /pmc/articles/PMC4590801/ /pubmed/26556196 http://dx.doi.org/10.1155/2014/490595 Text en Copyright © 2014 Sakshi Malhotra et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Malhotra, Sakshi
Khare, Anubha
Grover, Kanchan
Singh, Inderbir
Pawar, Pravin
Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title_full Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title_fullStr Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title_full_unstemmed Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title_short Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis
title_sort design and evaluation of voriconazole eye drops for the treatment of fungal keratitis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590801/
https://www.ncbi.nlm.nih.gov/pubmed/26556196
http://dx.doi.org/10.1155/2014/490595
work_keys_str_mv AT malhotrasakshi designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis
AT khareanubha designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis
AT groverkanchan designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis
AT singhinderbir designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis
AT pawarpravin designandevaluationofvoriconazoleeyedropsforthetreatmentoffungalkeratitis